Kyverna Therapeutics Aktie News

Topline-Durabilitätsdaten untermauern das Potenzial einer einmaligen Miv-cel-Dosis, Patienten von lebenslanger Krankheitslast und chronischen Immuntherapien zu befreien, und heben weiter das differenzierte Konstrukt von Miv-cel hervor

Die FDA gewährt die RMAT-Zulassung für miv-cel bei nicht-aktiver sekundärer progredienter Multipler Sklerose (naSPMS) auf Basis überzeugender klinischer Daten und erweitert damit das Potenzial der Therapie im Bereich Neuroimmunologie weiter.

EMERYVILLE, Calif., und WALTHAM, Mass.

EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026.

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date 1 Data reinforce miv-cel's differentiated clinical profile and oppo...

Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth

EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences: H.C.

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated